{"id":"placebo-group-once-daily","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebo is an inert substance used as a control in clinical trials to measure the effect of an active drug against baseline expectations and psychological factors. The placebo effect can result in symptom improvement due to patient expectation, conditioning, and natural disease progression rather than pharmacological action.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:33.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06097663","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-15","conditions":"Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)","enrollment":31},{"nctId":"NCT07485959","phase":"NA","title":"The Effect of NP-2006 on Sleep Quality and Health","status":"COMPLETED","sponsor":"Hanpoong Nature Pharm Co., Ltd.","startDate":"2023-05-12","conditions":"Sleep Disorder (Disorder)","enrollment":48},{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT06745921","phase":"PHASE1","title":"Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-24","conditions":"West Nile Viral Infection","enrollment":30},{"nctId":"NCT06757764","phase":"PHASE4","title":"The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-10","conditions":"Cerebral Infarction, Stenosis Artery","enrollment":2340},{"nctId":"NCT06009926","phase":"PHASE2","title":"Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-04","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm","enrollment":72},{"nctId":"NCT07244991","phase":"NA","title":"Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2026-01-04","conditions":"Dental Caries, Streptococcus Mutans, Tooth Demineralization","enrollment":200},{"nctId":"NCT06031844","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-16","conditions":"Coronary Heart Disease","enrollment":24},{"nctId":"NCT06939296","phase":"PHASE3","title":"A Research Study of VCT220 in Adult Chinese Participants With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2024-12-24","conditions":"Obesity, Overweight","enrollment":840},{"nctId":"NCT07201129","phase":"PHASE3","title":"A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment","status":"RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2026-02-09","conditions":"Nephritis, Lupus, Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT06082037","phase":"PHASE3","title":"A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-10-10","conditions":"Lung Transplant Rejection","enrollment":180},{"nctId":"NCT06752590","phase":"PHASE2","title":"A Clinical Study of ONO-1110 in Patients With Fibromyalgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-03-26","conditions":"Fibromyalgia","enrollment":160},{"nctId":"NCT07491458","phase":"PHASE2","title":"A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)","status":"RECRUITING","sponsor":"Rivus Pharmaceuticals, Inc.","startDate":"2026-02-13","conditions":"MASH - Metabolic Dysfunction-Associated Steatohepatitis","enrollment":180},{"nctId":"NCT07489612","phase":"PHASE2","title":"QLS1410 in Participants With Uncontrolled Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Hypertension (HTN)","enrollment":260},{"nctId":"NCT07388667","phase":"PHASE1","title":"A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-04","conditions":"Healthy","enrollment":120},{"nctId":"NCT06696755","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-02-03","conditions":"Bipolar I Disorder, Bipolar II Disorder","enrollment":195},{"nctId":"NCT07065240","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)","status":"RECRUITING","sponsor":"Seaport Therapeutics","startDate":"2025-06-19","conditions":"Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress","enrollment":360},{"nctId":"NCT07427017","phase":"PHASE2","title":"Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2026-02","conditions":"Ulcerative Colitis (UC)","enrollment":180},{"nctId":"NCT05711394","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-05-01","conditions":"Episodic Migraine","enrollment":450},{"nctId":"NCT06683508","phase":"PHASE2","title":"A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-11-13","conditions":"Obesity, Overweight","enrollment":288},{"nctId":"NCT07481981","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)","status":"NOT_YET_RECRUITING","sponsor":"Insmed Incorporated","startDate":"2026-04-17","conditions":"Pulmonary Arterial Hypertension","enrollment":344},{"nctId":"NCT06554301","phase":"PHASE1","title":"A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-10-20","conditions":"Pulmonary Arterial Hypertension","enrollment":72},{"nctId":"NCT07482085","phase":"PHASE3","title":"Efavirenz for the Treatment of Creutzfeldt-Jakob Disease","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-03","conditions":"Creutzfeldt-Jakob Disease","enrollment":246},{"nctId":"NCT06089317","phase":"NA","title":"Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2024-07-28","conditions":"Dry Eye Syndromes","enrollment":200},{"nctId":"NCT04944836","phase":"PHASE2","title":"Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-03-09","conditions":"Rotator Cuff Tears","enrollment":58},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT06462651","phase":"NA","title":"Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic","status":"COMPLETED","sponsor":"BioGaia AB","startDate":"2025-06-09","conditions":"Infantile Colic","enrollment":50},{"nctId":"NCT02531516","phase":"PHASE3","title":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-19","conditions":"Prostatic Neoplasms","enrollment":1503},{"nctId":"NCT07479056","phase":"NA","title":"Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention","status":"RECRUITING","sponsor":"SUK MIN SEO","startDate":"2024-10-24","conditions":"Diseases of the Circulatory System, Angina Pectoris, Unspecified","enrollment":400},{"nctId":"NCT05013112","phase":"NA","title":"Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2023-01-01","conditions":"Kidney Transplantation, Metabolic Disorder, Metformin","enrollment":105},{"nctId":"NCT06896669","phase":"NA","title":"Effects of Vitamin D and Calcium on Hyperglycemia and Dyslipidemia in Patients Gestational Diabetes","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2025-01-28","conditions":"Diabetes Mellitus, Gestational","enrollment":60},{"nctId":"NCT06562907","phase":"PHASE1","title":"Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-28","conditions":"Weight Management","enrollment":134},{"nctId":"NCT06721156","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-16","conditions":"Alzheimer Disease, Dementia","enrollment":350},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT04335656","phase":"PHASE2","title":"Reducing Innate Inflammation in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":"Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus","enrollment":60},{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":"Pulmonary Arterial Hypertension","enrollment":935},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT00663611","phase":"PHASE1","title":"Growth Hormone Administration and the Human Immune System","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2006-10-19","conditions":"Healthy Volunteers","enrollment":66},{"nctId":"NCT05523323","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":112},{"nctId":"NCT05327114","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-23","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":201},{"nctId":"NCT07469228","phase":"PHASE1","title":"A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2025-08-04","conditions":"Acne Vulgaris","enrollment":1043},{"nctId":"NCT07466030","phase":"PHASE1","title":"Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":"BPH (Benign Prostatic Hyperplasia)","enrollment":40},{"nctId":"NCT06079281","phase":"PHASE3","title":"Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-03","conditions":"Hypophosphatasia","enrollment":124},{"nctId":"NCT07466017","phase":"PHASE2","title":"A Study of CS060380 Tablets in Patients With MASH and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-04-14","conditions":"Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity","enrollment":120},{"nctId":"NCT07112872","phase":"PHASE2","title":"A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-08-19","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT05090904","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2021-11-30","conditions":"Cystic Fibrosis","enrollment":29},{"nctId":"NCT05182658","phase":"PHASE3","title":"Empagliflozin in Hypertrophic Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-06-01","conditions":"Hypertrophic Cardiomyopathy, Heart Failure","enrollment":250},{"nctId":"NCT06234501","phase":"NA","title":"Testing the Efficacy of 100mg Vitamin-B6 Daily for Sensory Reactivity in Autism","status":"RECRUITING","sponsor":"University of Reading","startDate":"2024-11-08","conditions":"Autism","enrollment":40},{"nctId":"NCT03626688","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2018-08-30","conditions":"PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension","enrollment":687},{"nctId":"NCT07456670","phase":"PHASE2","title":"Caffeine for Infants Born at 28 to 34 Weeks Receiving Respiratory Support","status":"NOT_YET_RECRUITING","sponsor":"Queen's University","startDate":"2026-04-01","conditions":"Preterm Birth, Caffeine, Neonatal Outcomes","enrollment":62},{"nctId":"NCT04910685","phase":"PHASE2, PHASE3","title":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","status":"RECRUITING","sponsor":"Blueprint Medicines Corporation","startDate":"2021-11-30","conditions":"Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis","enrollment":534},{"nctId":"NCT07462494","phase":"NA","title":"Probiotic Intervention in Constipation","status":"NOT_YET_RECRUITING","sponsor":"Wecare Probiotics Co., Ltd.","startDate":"2026-04-01","conditions":"Gastrointestinal Function","enrollment":30},{"nctId":"NCT07453212","phase":"NA","title":"Microbiome-Focused Food Supplement for Evaporative Dry Eye Due to Meibomian Gland Dysfunction","status":"ENROLLING_BY_INVITATION","sponsor":"Varol TUNALI","startDate":"2026-03-01","conditions":"Dry Eye, Evaporative Dry Eye Disease, Meibomian Gland Dysfunction (Disorder)","enrollment":130},{"nctId":"NCT07457008","phase":"PHASE1","title":"Tolerability & Pharmacokinetics of Ginkgolide B Injection: Single- and Multiple-Ascending Doses in Healthy Subjects","status":"COMPLETED","sponsor":"West China Second University Hospital","startDate":"2021-07-01","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT05423717","phase":"PHASE2","title":"Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2022-09-06","conditions":"Insomnia","enrollment":166},{"nctId":"NCT07456449","phase":"NA","title":"Collagen Peptides and Cellular Aging","status":"NOT_YET_RECRUITING","sponsor":"University of Vienna","startDate":"2026-02","conditions":"Longevity, Healthy Aging, Biological Ageing","enrollment":125},{"nctId":"NCT06444763","phase":"PHASE3","title":"Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2025-02-27","conditions":"Chronic Inflammation, Mobility, Muscle Pain","enrollment":97},{"nctId":"NCT07210463","phase":"PHASE3","title":"A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)","status":"RECRUITING","sponsor":"Merz Aesthetics GmbH","startDate":"2025-10-01","conditions":"Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs","enrollment":300},{"nctId":"NCT07298395","phase":"PHASE2","title":"Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Enveda Therapeutics","startDate":"2025-12-22","conditions":"Atopic Dermatitis (AD)","enrollment":64},{"nctId":"NCT07301255","phase":"PHASE2","title":"ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults","status":"RECRUITING","sponsor":"Enveda Therapeutics","startDate":"2026-01-09","conditions":"Asthma","enrollment":50},{"nctId":"NCT06747468","phase":"PHASE3","title":"Avexitide for Treatment of Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2025-04-29","conditions":"Post Bariatric Hypoglycemia","enrollment":75},{"nctId":"NCT07449910","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2026-03-17","conditions":"Acute Ichemic Stroke, Anterior Cerebral Artery Stroke, Baricitinib","enrollment":750},{"nctId":"NCT07179380","phase":"PHASE3","title":"Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","status":"RECRUITING","sponsor":"Insmed Incorporated","startDate":"2026-01-07","conditions":"Pulmonary Hypertension, Interstitial Lung Disease","enrollment":344},{"nctId":"NCT05889182","phase":"PHASE3","title":"A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-06-21","conditions":"Hidradenitis Suppurativa","enrollment":1328},{"nctId":"NCT07115056","phase":"PHASE4","title":"Extended Oral Tranexamic Acid After Anterior Cruciate Ligament Reconstruction","status":"WITHDRAWN","sponsor":"Campbell Clinic","startDate":"2026-04-01","conditions":"ACL Injury, ACL Tears, ACL Surgery","enrollment":""},{"nctId":"NCT07447518","phase":"EARLY_PHASE1","title":"Double j Stent Related Symptoms","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-09-22","conditions":"Lower Urinary Tract Symptoms","enrollment":535},{"nctId":"NCT07444892","phase":"PHASE2","title":"Levodopa for Diabetic Retinopathy","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-04-18","conditions":"Diabetic Retinopathy","enrollment":230},{"nctId":"NCT06308952","phase":"PHASE4","title":"Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation","status":"RECRUITING","sponsor":"Duan Chuanzhi","startDate":"2024-07-30","conditions":"Cerebrovascular Event, Stent Stenosis, Ischemic Stroke","enrollment":354},{"nctId":"NCT05672576","phase":"PHASE3","title":"A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2023-06-26","conditions":"Lupus Erythematosus, Systemic","enrollment":451},{"nctId":"NCT05648500","phase":"PHASE3","title":"A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2022-12-13","conditions":"Lupus Erythematosus, Systemic","enrollment":420},{"nctId":"NCT06286098","phase":"PHASE3","title":"Alpha Lipoic Acid in Pediatrics on Hemodialysis","status":"ENROLLING_BY_INVITATION","sponsor":"Ain Shams University","startDate":"2025-02-02","conditions":"Hemodialysis Complication, Pediatric Kidney Disease, Cardiovascular Complication","enrollment":50},{"nctId":"NCT06016842","phase":"PHASE3","title":"A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Ipsen","startDate":"2023-08-31","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":276},{"nctId":"NCT02932150","phase":"PHASE2","title":"Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":150},{"nctId":"NCT06708416","phase":"PHASE2","title":"A Study of ONO-1110 in Patients With Postherpetic Neuralgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-02-12","conditions":"Postherpetic Neuralgia","enrollment":140},{"nctId":"NCT04470622","phase":"PHASE2","title":"Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)","status":"TERMINATED","sponsor":"Heron Therapeutics","startDate":"2020-07-20","conditions":"COVID-19","enrollment":27},{"nctId":"NCT06481891","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy","status":"RECRUITING","sponsor":"Lexicon Pharmaceuticals","startDate":"2024-09-24","conditions":"Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy","enrollment":500},{"nctId":"NCT06568237","phase":"PHASE2","title":"A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2024-10-02","conditions":"Multiple System Atrophy","enrollment":350},{"nctId":"NCT07430280","phase":"NA","title":"Synbiotic Supplementation and Inflammation in Predialysis Chronic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Centenario Hospital Miguel Hidalgo","startDate":"2026-03-01","conditions":"Chronic Kidney Disease, Inflammation","enrollment":100},{"nctId":"NCT07400965","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-12-05","conditions":"Demodex Blepharitis","enrollment":250},{"nctId":"NCT06555783","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2024-07-26","conditions":"Narcolepsy Type 2","enrollment":93},{"nctId":"NCT06177535","phase":"NA","title":"A Study of Oral Kavalactones Effect on Nurses","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-08-05","conditions":"Stress","enrollment":200},{"nctId":"NCT07000357","phase":"PHASE3","title":"A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":"Cardiovascular Disease","enrollment":15100},{"nctId":"NCT07133438","phase":"PHASE4","title":"Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-08-01","conditions":"Retinal Vein Occlusion (RVO)","enrollment":120},{"nctId":"NCT06841536","phase":"NA","title":"Combined Effects of Statins and Exercise on Training Sensitive Health Markers","status":"COMPLETED","sponsor":"University of the Faroe Islands","startDate":"2025-05-01","conditions":"Dyslipidemias","enrollment":120},{"nctId":"NCT07433855","phase":"NA","title":"Efficacy and Safety of Heat-Treated Lactiplantibacillus Plantarum LM1004 on Immune Function","status":"COMPLETED","sponsor":"Soon Chun Hyang University","startDate":"2023-08-31","conditions":"Immune Function","enrollment":120},{"nctId":"NCT06422884","phase":"PHASE2","title":"A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Endeavor Biomedicines, Inc.","startDate":"2024-11-15","conditions":"Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease","enrollment":213},{"nctId":"NCT05577754","phase":"PHASE2","title":"Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-11-28","conditions":"Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)","enrollment":20},{"nctId":"NCT07414758","phase":"PHASE3","title":"Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-15","conditions":"Peripheral T Cell Lymphoma","enrollment":68},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT06223360","phase":"PHASE2","title":"A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)","status":"RECRUITING","sponsor":"Alzheimer's Disease Cooperative Study (ADCS)","startDate":"2024-03-28","conditions":"Alzheimer Disease","enrollment":406},{"nctId":"NCT07426705","phase":"PHASE4","title":"Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","startDate":"2026-02-15","conditions":"Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS","enrollment":100},{"nctId":"NCT03878589","phase":"PHASE2, PHASE3","title":"Understanding Cognition, Oxytocin & Pain in Elders","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-08-06","conditions":"Knee Osteoarthritis, Osteoarthritis","enrollment":83},{"nctId":"NCT06452095","phase":"NA","title":"Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-01-01","conditions":"Long COVID, Post Acute Sequelae of COVID-19, Post-COVID-19 Condition","enrollment":120},{"nctId":"NCT07371169","phase":"NA","title":"Efficacy of Chromium Picolinate in Reducing Acanthosis Nigricans Severity in Adolescents With Insulin Resistance","status":"COMPLETED","sponsor":"Uruk University","startDate":"2025-01-01","conditions":"Insulin Resistance, Acanthosis Nigricans","enrollment":90},{"nctId":"NCT07423533","phase":"PHASE2","title":"Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-02","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT06792136","phase":"PHASE2","title":"A Study of ONO-1110 in Patients With Major Depressive Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-01-16","conditions":"Major Depressive Disorder (MDD","enrollment":100},{"nctId":"NCT06805565","phase":"PHASE2","title":"A Study of ONO-1110 in Patients With Social Anxiety Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-01-16","conditions":"Social Anxiety Disorder (SAD)","enrollment":100},{"nctId":"NCT07007793","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-07","conditions":"Primary Hyperaldosteronism","enrollment":180},{"nctId":"NCT06248671","phase":"PHASE2","title":"Prophylactic Treatment With Atorvastatin for Episodic Migraine.","status":"RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2024-05-01","conditions":"Episodic Migraine","enrollment":450},{"nctId":"NCT07377136","phase":"NA","title":"Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.","status":"ENROLLING_BY_INVITATION","sponsor":"Charles University, Czech Republic","startDate":"2025-10-08","conditions":"Obesity & Overweight","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6682,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo group(once daily)","genericName":"Placebo group(once daily)","companyName":"LG Life Sciences","companyId":"lg-life-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}